Hizentra for the treatment of primary immunodeficiency

References

• Bruton OC. Agammaglobulinemia. Pediatrics 1952;9(6):722-8
   PubMed Web of Science ®Google Scholar
• Bousfiha AA, Jeddane L, Ailal F, et al. A phenotypic approach for IUIS PID classification and diagnosis: guidelines for clinicians at the bedside. J Clin Immunol 2013;33(6):1078-87
   PubMed Web of Science ®Google Scholar
• Bonilla FA, Bernstein IL, Khan DA, et al. Practice parameter for the diagnosis and management of primary immunodeficiency. Ann Allergy Asthma Immunol 2005;94(5 Suppl 1):S1-63
   PubMed Web of Science ®Google Scholar
• Al-Herz W, Bousfiha A, Casanova JL, et al. Primary immunodeficiency diseases: an update on the classification from the international union of immunological societies expert committee for primary immunodeficiency. Front Immunol 2014;5:162
   PubMed Web of Science ®Google Scholar
• Boyle JM, Buckley RH. Population prevalence of diagnosed primary immunodeficiency diseases in the United States. J Clin Immunol 2007;27(5):497-502
   PubMed Web of Science ®Google Scholar
• Bousfiha AA, Jeddane L, Ailal F, et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J Clin Immunol 2013;33(1):1-7
   PubMed Web of Science ®Google Scholar
• Notarangelo LD. Primary immunodeficiencies. J Allergy Clin Immunol 2010;125(2 Suppl 2):S182-94
   PubMed Web of Science ®Google Scholar
• Gaspar HB, Hammarstrom L, Mahlaoui N, et al. The case for mandatory newborn screening for severe combined immunodeficiency (SCID). J Clin Immunol 2014;34(4):393-7
   PubMedGoogle Scholar
• Cunningham-Rundles C, Bodian C. Common variable immunodeficiency: clinical and immunological features of 248 patients. Clin Immunol 1999;92(1):34-48
   PubMed Web of Science ®Google Scholar
• Yong PL, Boyle J, Ballow M, et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy Asthma and Immunology. Clin Immunol 2010;135(2):255-63
   PubMed Web of Science ®Google Scholar
• Janeway CA, Rosen FS. The gamma globulins. IV. Therapeutic uses of gamma globulin. N Engl J Med 1966;275(15):826-31
   PubMedGoogle Scholar
• Long AA, Denburg JA, Dent PB. Hypogammaglobulinemia: therapeutic rationale. CMAJ 1987;137(9):793-7
   PubMed Web of Science ®Google Scholar
• Hypogammaglobulinaemia in the United Kingdom. Summary report of a Medical Research Council working-party. Lancet 1969;1(7587):163-8
   PubMedGoogle Scholar
• Stiehm ER. Immunologic disorders in infants and children. 4th edition. W.B. Saunders; Philadelphia, PA, USA: 1996
   Google Scholar
• Eibl MM. History of immunoglobulin replacement. Immunol Allergy Clin North Am 2008;28(4):737-64, viii
   PubMed Web of Science ®Google Scholar
• Skoda-Smith S, Torgerson TR, Ochs HD. Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease. Ther Clin Risk Manag 2010;6:1-10
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Melamed I, Nelson RP, et al. Pharmacokinetics of subcutaneous IgPro20 in patients with primary immunodeficiency. Clin Pharmacokinet 2011;50(6):405-14
   PubMed Web of Science ®Google Scholar
• Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1987;1(8541):1075-7
   PubMed Web of Science ®Google Scholar
• Lucas M, Lee M, Lortan J, et al. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol 2010;125(6):1354-60. e4
   PubMed Web of Science ®Google Scholar
• Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin Immunol 2010;137(1):21-30
   PubMed Web of Science ®Google Scholar
• Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a review of evidence by members of the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma and Immunology. J Allergy Clin Immunol 2006;117(4 Suppl):S525-53
   PubMed Web of Science ®Google Scholar
• Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J Allergy Clin Immunol 2008;122(1):210-12
   PubMed Web of Science ®Google Scholar
• Immune Deficiency Foundation. Treatment experiences and preferences among patients with primary immunodeficiency diseases. National Survey of Patients (2008). Available from: http://primaryimmune.org/idf-survey-research-center/idf-surveys
   Google Scholar
• Immune Deficiency Foundation. Treatment experiences and preferences of patients with primary immune deficiency diseases: first national survey. 2003. Available from: http://primaryimmune.org/publications#idf_surveys
   Google Scholar
• Ballow M. Safety of IGIV therapy and infusion-related adverse events. Immunol Res 2007;38(1-3):122-32
   PubMedGoogle Scholar
• Berger M, Cupps TR, Fauci AS. Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 1980;93(1):55-6
   PubMedGoogle Scholar
• Gardulf A, Hammarstrom L, Smith CI. Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 1991;338(8760):162-6
   PubMed Web of Science ®Google Scholar
• Berger M. Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 2004;112(1):1-7
   PubMed Web of Science ®Google Scholar
• Jolles S, Bernatowska E, de Gracia J, et al. Efficacy and safety of Hizentra in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. Clin Immunol 2011;141(1):90-120
   PubMedGoogle Scholar
• US IVIG-SCIG forecast 2012-2017: for cost of the intravenous and subcutaneous immunoglobulin (IVIG/SCIG) market in the United States between 2012 and 2017. The Marketing Research Bureau, Inc; Orange, CT, USA: 2011
   Google Scholar
• US FDA. Immune globulins. 2014. Available from: www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaProducts/ucm127589.htm
   Google Scholar
• Shapiro R. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. J Clin Immunol 2010;30(2):301-7
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Melamed I, Stein MR, et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J Allergy Clin Immunol 2012;130(4):951-7. e11
   PubMed Web of Science ®Google Scholar
• Baxter Healthcare Corporation. HyQvia: immune globulin infusion 10% (human) with recombinant human hyaluronidase. 2014. Available from: www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM407013.pdf
   Google Scholar
• Maeder W, Lieby P, Sebald A, et al. Local tolerance and stability up to 24 months of a new 20% proline-stabilized polyclonal immunoglobulin for subcutaneous administration. Biologicals 2011;39(1):43-9
   PubMed Web of Science ®Google Scholar
• Wu G. Amino acids: metabolism, functions, and nutrition. Amino Acids 2009;37(1):1-17
   PubMed Web of Science ®Google Scholar
• Wu A. Tietz clinical guide to laboratory tests. 4th edition. Saunders; Philadelphia, PA, USA: 2006
   Google Scholar
• Hagan JB, Wasserman RL, Baggish JS, et al. Safety of L-proline as a stabilizer for immunoglobulin products. Expert Rev Clin Immunol 2012;8(2):169-78
   PubMed Web of Science ®Google Scholar
• Privigen. Immune globulin intravenous [human], 10% liquid Full prescribing information. CSL Behring, LLC, Kankakee, IL, USA. 2011
   Google Scholar
• Hizentra. In immune globulin subcutaneous (human), 20% liquid CSL Behring LLC Kankakee, IL, USA. 2013
   Google Scholar
• Stucki M, Boschetti N, Schafer W, et al. Investigations of prion and virus safety of a new liquid IVIG product. Biologicals 2008;36(4):239-47
   PubMed Web of Science ®Google Scholar
• Cai K, Groner A, Dichtelmuller HO, et al. Prion removal capacity of plasma protein manufacturing processes: a data collection from PPTA member companies. Transfus (Paris) 2013;53(9):1894-905
   Google Scholar
• Bonilla FA. Pharmacokinetics of immunoglobulin administered via intravenous or subcutaneous routes. Immunol Allergy Clin North Am 2008;28(4):803-19, ix
   PubMed Web of Science ®Google Scholar
• Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. BioDrugs 2007;21(2):105-16
   PubMed Web of Science ®Google Scholar
• Bonagura VR. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease. J Clin Immunol 2013;33(Suppl 2):S90-4
   PubMedGoogle Scholar
• Haddad E, Barnes D, Kafal A. Home therapy with subcutaneous immunoglobulins for patients with primary immunodeficiency diseases. Transfus Apher Sci 2012;46(3):315-21
   PubMed Web of Science ®Google Scholar
• Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics 2012;6:277-87
   PubMedGoogle Scholar
• Berger M, Rojavin M, Kiessling P, Zenker O. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Clin Immunol 2011;139(2):133-41
   PubMed Web of Science ®Google Scholar
• Berger M, Jolles S, Orange JS, Sleasman JW. Bioavailability of IgG administered by the subcutaneous route. J Clin Immunol 2013;33(5):984-90
   PubMed Web of Science ®Google Scholar
• Waniewski J, Gardulf A, Hammarstrom L. Bioavailability of gamma-globulin after subcutaneous infusions in patients with common variable immunodeficiency. J Clin Immunol 1994;14(2):90-7
   PubMed Web of Science ®Google Scholar
• Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340(3):227-8
   PubMed Web of Science ®Google Scholar
• Gardulf A, Nicolay U, Asensio O, et al. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies – a prospective, multi-national study. J Clin Immunol 2006;26(2):177-85
   PubMed Web of Science ®Google Scholar
• Landersdorfer CB, Bexon M, Edelman J, et al. Pharmacokinetic modeling and simulation of biweekly subcutaneous immunoglobulin dosing in primary immunodeficiency. Postgrad Med 2013;125(6):53-61
   PubMed Web of Science ®Google Scholar
• U.S. Department of Health and Human Services, Food and Drug Administration. Guidance for industry: statistical approaches to establishing bioequivalence. 2014. Available from: www.fda.gov/downloads/Drugs/Guidances/ucm070244.pdf
   Google Scholar
• Sidhu JS, Rojavin M, Berger M, et al. Pharmacokinetic modeling predicts different IgG exposures using different IVIG-SCIG dose conversion factors in patients with primary immune deficiency. J Allergy Clin Immunol 2014;133(2):AB181
   Google Scholar
• Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010;30(5):734-45
   PubMed Web of Science ®Google Scholar
• Kanegane H, Imai K, Yamada M, et al. Efficacy and safety of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency diseases. J Clin Immunol 2014;34(2):204-11
   PubMed Web of Science ®Google Scholar
• Jolles S, Borte M, Nelson RP Jr, et al. Long-term efficacy, safety, and tolerability of Hizentra® for treatment of primary immunodeficiency disease. Clin Immunol 2014;150(2):161-9
   PubMed Web of Science ®Google Scholar
• Imai K, Kanegane H, Yamada M, et al. Safety, tolerability, and efficacy of Hizentra® in Japanese patients with primary immunodeficiency over 48 weeks. J Allergy Clin Immunol 2014;133(2):AB182
   Google Scholar
• Food and Drug Administration and Center for Biologics Evaluation and Research. Guidance for industry: Safety, efficacy, and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. U.S. Department of Health and Human Services, Food and Drug Administration; 2005
   Google Scholar
• Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunoglobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26(3):265-73
   PubMed Web of Science ®Google Scholar
• Jones CA, Rojavin M, Baggish JS. Patients with primary immunodeficiency receiving subcutaneous immune globulin Hizentra maintain health-related quality of life and treatment satisfaction in a multicentre extension study of efficacy, tolerability and safety. J Pharm Health Serv Res 2012;3:41-7
   Google Scholar
• Nicolay U, Kiessling P, Berger M, et al. Health-related quality of life and treatment satisfaction in North American patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 2006;26(1):65-72
   PubMed Web of Science ®Google Scholar
• Berger M, Murphy E, Riley P, Bergman GE. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J 2010;103(9):856-63
   PubMed Web of Science ®Google Scholar
• Borte M, Bernatowska E, Ochs HD, Roifman CM. Efficacy and safety of home-based subcutaneous immunoglobulin replacement therapy in paediatric patients with primary immunodeficiencies. Clin Exp Immunol 2011;164(3):357-64
   PubMed Web of Science ®Google Scholar
• Meth MJ, Rosenthal DW, Bonagura VR. Subcutaneous immunoglobulin infusion to treat infants and toddlers with antibody deficiencies. Ann Allergy Asthma Immunol 2010;105(2):187-8
   PubMed Web of Science ®Google Scholar
• Sundin M, Nordin K, Jostemyr Y, Winiarski J. Subcutaneous IgG replacement after pediatric SCT. Pediatr Transplant 2012;16(8):866-71
   PubMed Web of Science ®Google Scholar
• Duff CM, Faulkner E, Schirm Z, et al. Effective use of subcutaneous immune globulin (SCIG) for an infant with X-linked agammaglobulinemia (X-LA). J Allergy Clin Immunol 2009;123(2):S64
   Google Scholar
• Shapiro RS. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics. Pediatr Allergy Immunol 2013;24(1):49-53
   PubMedGoogle Scholar
• Church JA, Howard V, Sleasman JW, et al. Subcutaneous immunoglobulin replacement therapy in infants and children with primary immunodeficiencies. J Allergy Clin Immunol 2011;127(2):AB213
   Google Scholar
• Haddad E, Berger M, Wang EC, et al. Higher doses of subcutaneous IgG reduce resource utilization in patients with primary immunodeficiency. J Clin Immunol 2012;32(2):281-9
   PubMedGoogle Scholar
• Orange JS, Belohradsky BH, Berger M, et al. Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. Clin Exp Immunol 2012;169(2):172-81
   PubMed Web of Science ®Google Scholar
• Berger M. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J Clin Immunol 2011;31(5):924-6
   PubMed Web of Science ®Google Scholar
• Huang F, Feuille E, Cunningham-Rundles C. Home care use of intravenous and subcutaneous immunoglobulin for primary immunodeficiency in the United States. J Clin Immunol 2013;33(1):49-54
   PubMed Web of Science ®Google Scholar
• Shapiro RS, Wasserman RL, Bonagura V, Gupta S. Emerging paradigm of primary immunodeficiency disease: individualizing immunoglobulin dose and delivery to enhance outcomes. J Clin Immunol 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Fadeyi M, Tran T. Calculating the dose of subcutaneous immunoglobulin for primary immunodeficiency disease in patients switched from intravenous to subcutaneous immunoglobulin without the use of a dose-adjustment coefficient. P T 2013;38(12):768-70
   PubMedGoogle Scholar
• Shapiro R. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Clin Exp Immunol 2013;173(2):365-71
   PubMed Web of Science ®Google Scholar
• Shapiro RS. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Ann Allergy Asthma Immunol 2013;111(1):51-5
   PubMed Web of Science ®Google Scholar
• Wasserman RL, Fatteh S, Khan JM, Haddad E. Retrospective analysis of the clinical utility of biweekly dosing with high-concentration subcutaneous immunoglobulin in 10 patients with primary immunodeficiency. J Allergy Clin Immunol 2014;133(2):AB184
   Google Scholar
• Malcolmson C, Jones A. Safety and efficacy of biweekly Hizentra® administration in patients with primary immunodeficiency diseases: A retrospective single-center study. J Allergy Clin Immunol 2014;133(2):AB180
   Google Scholar
• Magy L, Ghorab K, Calvo J, Vallat JM. Subcutaneous immunoglobulin as maintenance therapy in intravenous immunoglobulin-responsive CIDP patients. Long-term response in 16 patients. J Peripher Nerv Syst 2009;14:94
   Google Scholar
• Cocito D, Serra G, Falcone Y, Paolasso I. The efficacy of subcutaneous immunoglobulin administration in chronic inflammatory demyelinating polyneuropathy responders to intravenous immunoglobulin. J Peripher Nerv Syst 2011;16(2):150-2
   PubMed Web of Science ®Google Scholar
• Lee DH, Linker RA, Paulus W, et al. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2008;37(3):406-9
   PubMed Web of Science ®Google Scholar
• Zampelli A, Zacek L, Levasseur MC. Successful use of subcutaneous immunoglobulin in chronic neurology patients. Neurology 2012;78:1
   Google Scholar
• Kazamel M, Sultan S, Alsharabati M, et al. Subcutaneous immunoglobulin use in neuromuscular patients who could not use or tolerate intravenous immunoglobulin: case series. J Clin Neuromuscular Dis 2013;14(3):154
   Google Scholar
• Misbah S, Comi G, Fazio R, et al. Efficacy and safety of subcutaneous immunoglobulin, Vivaglobin, in patients with multifocal motor neuropathy. J Neurol 2010;257(Suppl 1):S105-6
   Google Scholar
• Dacci P, Riva N, Scarlato M, et al. Subcutaneous immunoglobulin therapy for the treatment of multifocal motor neuropathy: a case report. Neurol Sci 2010;31(6):829-31
   PubMed Web of Science ®Google Scholar
• Schleinitz N, Jean E, Benarous L, et al. Subcutaneous immunoglobulin administration: an alternative to intravenous infusion as adjuvant treatment for dermatomyositis? Clin Rheumatol 2008;27(8):1067-8
   PubMedGoogle Scholar
• Danieli MG, Moretti R, Gambini S, et al. Open-label study on treatment with 20 % subcutaneous IgG administration in polymyositis and dermatomyositis. Clin Rheumatol 2014;33(4):531-6
   PubMed Web of Science ®Google Scholar